Description du projet
Orienter les efforts de mise au point d’un vaccin contre le paludisme vers différentes espèces de parasites
Plasmodium vivax est une espèce de protozoaire parasite qui provoque une forme moins grave de paludisme que Plasmodium falciparum. P. vivax a la capacité unique de former des stades hépatiques dormants responsables de la rechute de la maladie des mois, voire des années après l’infection initiale. Sa prévalence généralisée est très préoccupante. Financé par le programme HORIZON, le projet OptiViVax vise à accélérer la recherche et le développement de vaccins de nouvelle génération en s’appuyant des approches innovantes. Les chercheurs prévoient d’élargir le portefeuille d’antigènes pour les essais cliniques et d’étudier de nouvelles plates-formes d’administration et de nouveaux adjuvants. La compréhension des mécanismes de la protection médiée par les anticorps, ainsi que les progrès de la recherche et des outils cliniques, contribueront à une conception optimale des vaccins.
Objectif
Plasmodium vivax is the most widespread human malaria with 2.5 billion people living at risk in South America, Oceania and Asia. The revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria, calling for a vaccine intervention to achieve 75% efficacy over two years, now equally weighted with P. falciparum. However, if this ambition is to be realised, new and innovative approaches are urgently required to accelerate next-generation vaccine research and development, whilst the few known candidate antigens need to undergo early-phase clinical assessment.
Here, we build on exciting breakthroughs in P. vivax vaccine research, recently pioneered in Europe, including new transgenic parasite technologies for functional assay development and production of a parasite clone that is safe for use in controlled human malaria infection (CHMI) clinical models. The Objectives of OptiViVax will now integrate ambitious multi-disciplinary scientific and clinical approaches around the parasite’s lifecycle and will use our increased knowledge of P. vivax immuno-biology to further develop next-generation vaccines with improved efficacy. We will diversify the portfolio of new antigens ready for clinical testing by reverse vaccinology and diversify their delivery with new platforms and adjuvants developed using sustainable and improved GMP bio-manufacturing know-how. In parallel, the efficacy of known leading antigens will be benchmarked for the first time using innovative design of clinical studies and CHMI models making these lead candidate vaccines ready for future field trials. Improved preclinical functional assays, using state-of-the-art transgenic parasite lines, will also allow for mechanisms of antibody-mediated protection to be deciphered. The availability of new functional assays and human challenge models will underpin the future framework for informed decision making by the clinical vaccine community, policy makers, funders and regulators.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
6525 GA Nijmegen
Pays-Bas